BioWorld

April 22, 2008

Survival Data Could Threaten Avastin in Lung Cancer Market

Analysts are predicting that Genentech Inc.'s Avastin could face stiff competition as a treatment for lung cancer from ImClone Systems Inc.'s Erbitux (Cetuximab) based on new data. (BioWorld Today) Read More

Series B Round Gains $25M for Stromedix Fibrosis Trial

Inflammation Increases Fusion of Brain with Blood Stem Cells

Vernalis Takes $29M for Now, Giving Up Migraine Revenues

Other News To Note

Clinic Roundup

ECCMID Roundup

Today's news in brief

BioWorld

BioWorld briefs for July 21, 2026.

ALN-5288 lowers tau levels in preclinical models

BioWorld Science

Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....

LIT-002 is strong candidate for autism and neuropathic pain

BioWorld Science

Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 21, 2026

New biomarker may improve RSV drug screening

BioWorld

Respiratory syncytial virus (RSV) infection is responsible for 3.2 million hospital admissions and about 118,000 deaths in children under 5 years of age. The...